A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors (NCT05812027)
Screening Study to Determine HLA Type, HLA Loss of Heterozygosity Status and Tumor Antigen Expression in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participants meet the eligibility criteria for these parameters and could potentially be enrolled in a TScan clinical study.
Who can join: Review the eligibility criteria below.
Location: HonorHealth Research and Innovation Institute — Scottsdale, Arizona
Age range: 18 Years
🧪 Interventions in This Study
- Tumor and HLA Profiling (DIAGNOSTIC_TEST)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (21 Sites)
- HonorHealth Research and Innovation Institute — Scottsdale, Arizona
- University of California San Diego — San Diego, California
- Yale Cancer Center — New Haven, Connecticut
- Memorial Healthcare System — Hollywood, Florida
- University of Miami, Sylvester Comprehensive Cancer Center — Miami, Florida
- Orlando Health — Orlando, Florida
- University of South Florida — Tampa, Florida
- University of Chicago — Chicago, Illinois
- Norton Cancer Institute — Louisville, Kentucky
- Karmanos Cancer Institute — Detroit, Michigan
- University of Minnesota, Masonic Cancer Center — Minneapolis, Minnesota
- Columbia University Herbert Irving Comprehensive Cancer Center — New York, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Oncology Hematology Care — Cincinnati, Ohio
- The Cleveland Clinic — Cleveland, Ohio
- OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma
- Providence Cancer Institute Franz Clinic — Portland, Oregon
- Allegheny Hospitals Network — Pittsburgh, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Sarah Cannon Research Institute — Nashville, Tennessee
- Baylor College of Medicine — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Head and Neck Cancer
- Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity — Boston, Massachusetts
- Imaging With a PET Agent for Detection of Cancers of the Head and Neck — New York, New York
- Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Head and Neck Cancer — Miami, Florida
- ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy — Miami, Florida
- ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer — Bethesda, Maryland
- "QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer — Oklahoma City, Oklahoma
Explore by condition: All Head and Neck Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.